Novo Holdings Arcellx, Inc. Transaction History

Novo Holdings

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$31.51 - $37.4 $2.36 Million - $2.81 Million	75,000 Added 7.5%	1,075,000 $38.6 Million
Q2 2023 Aug 14, 2023	SELL	$27.49 - $46.9 $6.19 Million - $10.6 Million	-225,000 Reduced 18.37%	1,000,000 $31.6 Million
Q1 2023 May 15, 2023	SELL	$26.92 - $33.94 $6.97 Million - $8.79 Million	-259,020 Reduced 17.45%	1,225,000 $37.7 Million
Q4 2022 Feb 14, 2023	SELL	$17.18 - $33.0 $29.3 Million - $56.4 Million	-1,707,858 Reduced 53.51%	1,484,020 $46 Million
Q3 2022 Nov 14, 2022	SELL	$16.67 - $22.04 $13.8 Million - $18.2 Million	-825,000 Reduced 20.54%	3,191,878 $59.9 Million
Q1 2022 May 16, 2022	BUY	$12.97 - $19.14 $52.1 Million - $76.9 Million	4,016,878 New	4,016,878 $56.3 Million

204

44.2M

2.23M

907K

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $3.47B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

Get notified when there are updates to the investment portfolio of Novo Holdings, based on Form 13F filings with the SEC.

Stay updated on Novo Holdings with notifications on news.